Last Price$177.02.3%
Market Cap$19.6B
P/EBITDA LTM
9.5x
5Y avg
7.9x
Medical - Diagnostics & Research industry
median
(0.7x)
Stock quality & Intrinsic value
6/10
1.1% undervalued
Quest Diagnostics Incorporated P/EBITDA LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/EBITDA LTM | 12.1x | 9.3x | 8.3x | 9.2x | 7.2x | 7.1x | 5.5x | 7.2x | 5.8x | 4.4x | 7.4x | 6.5x | 8.7x | 9.3x | 7.6x | 10.1x | 8.1x | 6.1x | 8.0x | 9.6x |
Overvalued or undervalued?
Check the intrinsic value for DGX
and see if it's the right time to invest.
Quest Diagnostics Incorporated (DGX) P/EBITDA LTM comparison analysis
General
LTM P/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Quest Diagnostics IncorporatedDGX
11.2x
(6.4%)
(6.5%)
9.2%
Median Peer Set
21.9x
(0.1%)
2.4%
16.3%
IDEXX Laboratories, Inc.IDXX
29.2x
8.7%
25.2%
23.1%
Waters CorporationWAT
22.5x
(0.5%)
(7.9%)
21.7%
Danaher CorporationDHR
22.4x
(0.1%)
(17.9%)
16.3%
Agilent Technologies, Inc.A
22.1x
(4.7%)
5.0%
19.8%
Mettler-Toledo International Inc.MTD
21.9x
2.2%
12.7%
22.3%
Thermo Fisher Scientific Inc.TMO
19.2x
(4.6%)
(12.4%)
14.0%
IQVIA Holdings Inc.IQV
9.9x
2.8%
2.4%
8.9%
Illumina, Inc.ILMN
(16.6x)
(2.9%)
4.6%
(28.0%)
Natera, Inc.NTRA
(113.7x)
32.0%
(32.1%)
(40.2%)
DGX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 5,126.6 0.0% | 5,503.7 7.4% | 6,268.7 13.9% | 6,704.9 7.0% | 7,249.4 8.1% | 7,455.2 2.8% | 7,368.9 (1.2%) | 7,510.5 1.9% | 7,382.6 (1.7%) | 7,146.0 (3.2%) | 7,435.0 4.0% | 7,493.0 0.8% | 7,515.0 0.3% | 7,709.0 2.6% | 7,531.0 (2.3%) | 7,726.0 2.6% | 9,437.0 22.1% | 10,788.0 14.3% | 9,883.0 (8.4%) | 9,252.0 (6.4%) |
| Cost of Goods Sold (COGS) | 2,990.7 | 3,257.3 | 3,696.0 | 3,969.8 | 4,256.1 | 4,321.5 | 4,317.2 | 4,395.3 | 4,364.7 | 4,326.0 | 4,637.0 | 4,657.0 | 4,616.0 | 4,719.0 | 4,926.0 | 5,037.0 | 5,804.0 | 6,579.0 | 6,450.0 | 6,291.0 |
% margin | 2,135.9 41.7% | 2,246.4 40.8% | 2,572.7 41.0% | 2,735.1 40.8% | 2,993.3 41.3% | 3,133.7 42.0% | 3,051.7 41.4% | 3,115.2 41.5% | 3,017.9 40.9% | 2,820.0 39.5% | 2,798.0 37.6% | 2,836.0 37.8% | 2,899.0 38.6% | 2,990.0 38.8% | 2,605.0 34.6% | 2,689.0 34.8% | 3,633.0 38.5% | 4,209.0 39.0% | 3,433.0 34.7% | 2,961.0 32.0% |
| Operating Expenses | 1,234.4 | 1,278.3 | 1,444.6 | 1,643.7 | 1,770.9 | 1,774.6 | 1,756.2 | 2,120.2 | 1,817.1 | 1,819.0 | 1,815.0 | 1,771.0 | 1,740.0 | 1,825.0 | 1,500.0 | 1,458.0 | 1,662.0 | 1,828.0 | 2,005.0 | 1,761.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 1,227.7 | 1,257.8 | 1,433.7 | 1,612.9 | 1,736.9 | 1,747.6 | 1,707.7 | 1,814.3 | 1,745.2 | 1,704.0 | 1,728.0 | 1,679.0 | 1,681.0 | 1,750.0 | 1,424.0 | 1,457.0 | 1,550.0 | 1,727.0 | 1,874.0 | 1,615.0 |
% margin | 901.4 17.6% | 968.1 17.6% | 1,128.0 18.0% | 1,091.3 16.3% | 1,222.4 16.9% | 1,359.1 18.2% | 1,295.5 17.6% | 995.0 13.2% | 1,200.8 16.3% | 1,475.0 20.6% | 983.0 13.2% | 1,399.0 18.7% | 1,277.0 17.0% | 1,165.0 15.1% | 1,101.0 14.6% | 1,231.0 15.9% | 1,971.0 20.9% | 2,381.0 22.1% | 1,428.0 14.4% | 1,262.0 13.6% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 5.7 | 2.5 | 1.4 | 2.8 | 3.0 | 3.0 | 3.0 | 1.0 | 1.0 | 2.0 | 2.0 | 5.0 | 3.0 | 1.0 | 10.0 | 11.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 185.5 | 144.1 | 146.1 | 170.6 | 164.7 | 159.0 | 164.0 | 153.0 | 143.0 | 151.0 | 167.0 | 175.0 | 163.0 | 151.0 | 138.0 | 163.0 |
| Pre-tax Income | 835.1 | 910.5 | 1,033.3 | 912.4 | 1,019.0 | 1,227.9 | 1,184.3 | 856.3 | 1,068.4 | 1,348.0 | 849.0 | 1,103.0 | 1,086.0 | 1,030.0 | 926.0 | 1,076.0 | 1,884.0 | 2,599.0 | 1,235.0 | 1,130.0 |
% effective tax rate | 335.9 40.2% | 364.2 40.0% | 407.6 39.4% | 358.6 39.3% | 386.8 38.0% | 460.4 37.5% | 425.5 35.9% | 349.0 40.8% | 401.9 37.6% | 500.0 37.1% | 262.0 30.9% | 373.0 33.8% | 429.0 39.5% | 241.0 23.4% | 182.0 19.7% | 247.0 23.0% | 460.0 24.4% | 597.0 23.0% | 264.0 21.4% | 248.0 21.9% |
% margin | 499.2 9.7% | 546.3 9.9% | 586.4 9.4% | 339.9 5.1% | 581.5 8.0% | 729.1 9.8% | 720.9 9.8% | 470.6 6.3% | 555.7 7.5% | 849.0 11.9% | 556.0 7.5% | 709.0 9.5% | 645.0 8.6% | 772.0 10.0% | 736.0 9.8% | 858.0 11.1% | 1,431.0 15.2% | 1,995.0 18.5% | 946.0 9.6% | 854.0 9.2% |
| EPS | 2.45 | 2.71 | 2.98 | 1.76 | 2.99 | 3.91 | 4.08 | 2.95 | 3.49 | 5.58 | 3.83 | 4.92 | 4.58 | 5.63 | 5.41 | 6.38 | 10.68 | 15.90 | 8.12 | 7.59 |
| Diluted EPS | 2.35 | 2.66 | 2.94 | 1.74 | 2.97 | 3.87 | 4.05 | 2.92 | 3.46 | 5.54 | 3.81 | 4.87 | 4.51 | 5.50 | 5.29 | 6.29 | 10.52 | 15.53 | 7.98 | 7.52 |
% margin | 1,049.6 20.5% | 1,183.7 21.5% | 1,325.4 21.1% | 1,329.2 19.8% | 1,500.7 20.7% | 1,631.2 21.9% | 1,585.8 21.5% | 1,302.0 17.3% | 1,523.0 20.6% | 1,793.0 25.1% | 1,304.0 17.5% | 1,555.0 20.8% | 1,479.0 19.7% | 1,453.0 18.8% | 1,404.0 18.6% | 1,585.0 20.5% | 2,411.0 25.5% | 3,159.0 29.3% | 1,820.0 18.4% | 1,732.0 18.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Quest Diagnostics Incorporated's P/EBITDA LTM?
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is 9.5x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/EBITDA LTM for Quest Diagnostics Incorporated have been 7.6x over the past three years, and 8.3x over the past five years.
2) Is Quest Diagnostics Incorporated's P/EBITDA LTM Good?
As of today, Quest Diagnostics Incorporated's P/EBITDA LTM is 9.5x, which is higher than industry median of (0.7x). It indicates that Quest Diagnostics Incorporated's P/EBITDA LTM is Bad.